Company news

Nektar Therapeutics news in 2024

Nektar Therapeutics's news releases, calls and decks from 2024, newest first.

View company

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

December 6, 2024

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

November 17, 2024

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

November 6, 2024

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 6, 2024

Nektar Therapeutics to Participate in Upcoming Investor Conferences

November 5, 2024

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

November 3, 2024

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

October 30, 2024

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

October 28, 2024

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

October 16, 2024

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

September 24, 2024

Nektar Management to Present at Upcoming Investor Conferences

September 2, 2024

Nektar Therapeutics Reports Second Quarter 2024 Financial Results

August 7, 2024

Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets

July 31, 2024

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

June 11, 2024

Nektar Therapeutics Reports First Quarter 2024 Financial Results

May 8, 2024

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

May 1, 2024

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

March 21, 2024

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

March 4, 2024

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

March 3, 2024

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

March 3, 2024

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

February 26, 2024

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

February 25, 2024

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

January 2, 2024

Calls in 2024

Decks in 2024